FUNDACION PARA LA INVESTIGACION BIOSANITARIA DE ANDALUCIA ORIENTAL-ALEJANDRO OTERO

Their core work

FIBAO is a biomedical research foundation based in Granada, Spain, supporting clinical and translational health research in the Andalusian public health system. They contribute patient cohorts, biobank infrastructure, and clinical expertise to large European studies on autoimmune diseases, tinnitus, and infectious disease surveillance. Their work bridges hospital-based clinical practice with multi-center research, providing real-world patient data and biological samples to international consortia.

What they specialise in

How they've shifted over time

FIBAO's early H2020 involvement (2017–2019) centered on autoimmune disease research and molecular stratification, contributing to complex genomics-driven projects like 3TR. From 2020 onward, their focus shifted toward tinnitus as a personalized medicine challenge and pandemic-driven epidemiological surveillance through I-MOVE-COVID-19. This suggests a foundation that responds to both long-term clinical specializations and urgent public health needs.

FIBAO is moving toward personalized medicine approaches and real-world clinical data integration, making them a strong partner for projects needing patient stratification and biobank access in Southern Europe.

How they like to work

FIBAO operates almost exclusively as a third-party contributor (3 of 4 projects), meaning they provide specific clinical expertise, patient access, or biobank resources to larger consortia without leading project management. They have never coordinated an H2020 project. Despite their supporting role, they connect to a wide network of 132 unique partners across 23 countries, indicating they are trusted clinical contributors sought out by major European consortia.

FIBAO has collaborated with 132 unique partners across 23 countries, a remarkably broad network for an organization with only 4 projects — reflecting the large consortium sizes typical of health research. Their reach spans most of Europe through major multi-center clinical studies.

What sets them apart

FIBAO offers something many research foundations cannot: direct access to the Andalusian public health system's patient populations and clinical infrastructure, embedded within a large European network. Their dual specialization in tinnitus research and autoimmune disease makes them an unusual combination — few organizations bridge these two fields. For consortium builders, they represent a reliable Spanish clinical site with biobanking capability and established third-party participation experience.

Highlights from their portfolio

• 3TR
  A flagship health project (2019–2026) tackling treatment non-response across autoimmune diseases using advanced genomics, single-cell data, and predictive modeling — one of the most ambitious patient stratification efforts in H2020.
• I-MOVE-COVID-19
  Rapid-response pandemic project demonstrating FIBAO's ability to mobilize clinical surveillance infrastructure for urgent public health crises across European hospital networks.
• UNITI
  Focused effort to unify tinnitus treatment approaches through personalized medicine and biobanking, directly complementing FIBAO's ESIT training network involvement.